Open Access

Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of PDGFRA, VEGFR2 and KIT: A case report

  • Authors:
    • Haruki Matsuoka
    • Ken-Ichi Yoshida
    • Sho Nakai
    • Rie Suzuki
    • Yoshinori Imura
    • Haruna Takami
    • Makiyo Watanabe
    • Toru Wakamatsu
    • Hironari Tamiya
    • Hidetatsu Outani
    • Toshinari Yagi
    • Shigeki Kakunaga
    • Satoshi Takenaka
  • View Affiliations

  • Published online on: July 29, 2024     https://doi.org/10.3892/mco.2024.2767
  • Article Number: 69
  • Copyright: © Matsuoka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Undifferentiated pleomorphic sarcoma (UPS) is a high‑grade, aggressive soft tissue sarcoma (STS) with a poor prognosis, and no definitive or effective treatment is currently available for it. Pazopanib, an orally available multiple tyrosine kinase inhibitor, has been approved for the treatment of advanced STS. The present study documents the case of a 51‑year‑old man with advanced UPS with coamplification of platelet‑derived growth factor receptor A (PDGFRA), vascular endothelial growth factor receptor 2 (VEGFR2) and stem cell factor receptor (KIT) genes. The patient exhibited a marked and sustained response to pazopanib. The patient presented with a retroperitoneal tumour with pancreatic head lymph node metastasis, and bone metastases in the second/fifth thoracic vertebrae and left femur. Based on the histological analysis of the retroperitoneal tumour and femoral mass, the patient was diagnosed with UPS. Palliative radiation therapy was administered to the left femur and second/fifth thoracic vertebrae to prevent fractures. After radiation therapy, the patient achieved a partial response after eight courses of doxorubicin. A comprehensive genomic profiling analysis (FoundationOne® CDx) revealed coamplification of PDGFRA, VEGFR2 and KIT genes. Hence, pazopanib was initiated as a second‑line treatment. Notably, the retroperitoneal tumour shrank, and no new lesions developed for 3 years after the initiation of pazopanib treatment. This response suggests that the coamplification of PDGFRA, VEGFR2 and KIT may predict favourable outcomes in response to pazopanib.
View Figures
View References

Related Articles

Journal Cover

October-2024
Volume 21 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Matsuoka H, Yoshida K, Nakai S, Suzuki R, Imura Y, Takami H, Watanabe M, Wakamatsu T, Tamiya H, Outani H, Outani H, et al: Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of <em>PDGFRA</em>, <em>VEGFR2</em> and <em>KIT</em>: A case report. Mol Clin Oncol 21: 69, 2024.
APA
Matsuoka, H., Yoshida, K., Nakai, S., Suzuki, R., Imura, Y., Takami, H. ... Takenaka, S. (2024). Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of <em>PDGFRA</em>, <em>VEGFR2</em> and <em>KIT</em>: A case report. Molecular and Clinical Oncology, 21, 69. https://doi.org/10.3892/mco.2024.2767
MLA
Matsuoka, H., Yoshida, K., Nakai, S., Suzuki, R., Imura, Y., Takami, H., Watanabe, M., Wakamatsu, T., Tamiya, H., Outani, H., Yagi, T., Kakunaga, S., Takenaka, S."Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of <em>PDGFRA</em>, <em>VEGFR2</em> and <em>KIT</em>: A case report". Molecular and Clinical Oncology 21.4 (2024): 69.
Chicago
Matsuoka, H., Yoshida, K., Nakai, S., Suzuki, R., Imura, Y., Takami, H., Watanabe, M., Wakamatsu, T., Tamiya, H., Outani, H., Yagi, T., Kakunaga, S., Takenaka, S."Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of <em>PDGFRA</em>, <em>VEGFR2</em> and <em>KIT</em>: A case report". Molecular and Clinical Oncology 21, no. 4 (2024): 69. https://doi.org/10.3892/mco.2024.2767